Viewing nowTarek Film-coated Tablets 40mg (Valsartan)
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

MFDS item code 200511380 · Notified 2005.10.27
This product's status changed to Company closed on 2023.07.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension, reduction of the risk of death after myocardial infarction, treatment of heart failure
This medication is used for patients with essential hypertension and heart failure, particularly those who cannot use ACE inhibitors. It is also effective in reducing the risk of death in patients with impaired left ventricular function after myocardial infarction. Therefore, it is used for management of hypertension, improvement of cardiac function, and reduction of mortality risk after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose must not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consideration should be given to reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily; thereafter, over several weeks, the dose may be increased according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is required when creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if administered to pregnant women, so it must be discontinued immediately upon confirmation of pregnancy. Patients with a history of allergic reactions to this medication, severe liver disease, kidney impairment, or a history of specific angioedema should not use it. Elderly patients, patients with hyperkalemia, patients with impaired liver function, and patients with heart valve disease should use this medication cautiously, as blood pressure may drop too low. During the course of treatment, dizziness, headache, fatigue, cough, gastrointestinal symptoms, etc., may occur, and patients with heart failure or myocardial infarction may experience changes in kidney function and hypotension, necessitating regular check-ups. As blood pressure may drop suddenly, leading to fainting, it is important to start with a low dose and closely monitor the patient's condition when taking it for the first time. Caution is advised when taken with potassium-sparing diuretics or potassium supplements, as blood potassium levels may rise to hazardous levels. Additionally, when taken with other antihypertensives or some non-steroidal anti-inflammatory drugs, the blood pressure control effect may decrease or affect kidney function, so consultation with a physician is necessary. It is recommended that pregnant or breastfeeding women avoid taking this medication, and women planning to become pregnant should consult a doctor before taking it. The safety and efficacy in children and adolescents under 18 years of age have not been established.
headache
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is also important to store it in a cool place below 30 degrees Celsius to maintain the drug's effectiveness.
Yellow oval film-coated tablets
98 tablets (14 tablets/PTP packaging x 7)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Dongkwang Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.